🧬 Could CAR T-cell therapy offer a new way to treat lung cancer?

It’s already transforming treatment for some blood cancers. Now researchers are exploring whether CAR T-cell therapy could help tackle lung cancer, including cancers that develop resistance to targeted therapies. Join ALK Positive and EGFR Resisters tomorrow (Sunday, Oct 18th) for a special joint ALKtALK with Dr Kyle Concannon, thoracic oncologist and physician-scientist at the University of Colorado Anschutz Medical Campus. Dr Concannon and team are developing ACES CAR T cells, an experimental approach with potential applications across ALK, EGFR, HER2 and other oncogene-driven lung cancers. 💙 What makes this research particularly exciting? It explores whether specially engineered immune cells could offer an entirely different way to target cancer cells. We’ll discuss how the science works, where the research stands today and what needs to happen before the first clinical trial. 🎤 Plus, a live Q&A with Dr Concannon! Bring your questions and hear directly from the scientist developing this approach. 📅 Sunday, October 18 ⏰ 7 p.m. ET 🔗 Register through the link in our bio! Many patient communities. One shared goal: more treatment options for everyone. 💙 #ALKPositive #EGFR #LungCancer #CARTCellTherapy